Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study and Dose Seeking Study of an Intravenous Formulation of the Anthracycline Analog GPX-150 in Patients With Solid Tumors

NCT00710125 is registered in ClinicalTrials.gov with Gem Pharmaceuticals as lead sponsor.

NCT NCT00710125
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00710125 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study and Dose Seeking Study of an Intravenous Formulation of the Anthracycline Analog GPX-150 in Patients With Solid Tumors
Lead sponsor
Gem Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2008
Completion date
October 31, 2013
Enrollment
27 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors - phase 1 population